Investors considering Canopy Growth may want to wait for the U.S. Drug Enforcement Administration's decision on rescheduling cannabis before buying shares. The DEA's move to reclassify marijuana to Schedule III has been in progress for months, with recent hearings fueling optimism, and President Trump's December executive order calling for expedited action could accelerate a final ruling. A favorable decision would allow Canopy Growth to move closer to consolidating its U.S. affiliate, Canopy USA, and would relieve Canopy USA from Internal Revenue Code section 280E deduction limits. However, past price action shows that cannabis stocks often surge on rescheduling headlines only to retreat afterward, suggesting that waiting for the market to digest the news may be the better strategy for long-term investors.
Canopy Growth CorpDEA rescheduling decision is pending; favorable outcome would benefit Canopy Growth, but past price action suggests potential sell-off after news.